DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

“By rescuing failing heart muscle, we directly address the underlying pathology of heart failure. The unprecedented ... is a first-in-class therapy designed to repair the root cause of failing ...

UK: In a secondary analysis of the FINEARTS-HF randomized clinical trial, researchers found that finerenone, a novel ...

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound, included ...

The newest class ... GLP-1 agonist medications. According to a new international study known as the SUMMIT trial, there may ...

Occasionally, maneuvers to protect the integrity of the airway may be needed. In a heart failure patient having previously experienced ACE inhibitor-related angioedema, ARBs should be used ...

Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein ≥2 mg/L; p=0.003) and ischemic HFrEF etiology ...

The recipient had been suffering from dilated cardiomyopathy, a severe heart condition where the heart muscles become weak, ...

These changes are usually reversed within 1 hour once diuresis begins ... on survival in severely symptomatic (New York Heart Association class IV) heart failure patients taking an ACE inhibitor ...

The test of tirzepatide, brand named Zepbound, included 731 patients with diastolic heart failure and obesity who were followed for two years. "This class of drugs continue to show benefits far ...

The release says that 56 of the placebo recipients died or suffered worsening heart failure during the study, compared to 36 of those getting the drug. Additionally, patients using the drug were more ...